Mavacamten (CAMZYOS) is a reversible actin inhibitor, mainly used for the treatment of obstructive hypertrophic cardiomyopathy (HCM).

What are the indications for Mavacamten (CAMZYOS)

 Since the metabolism and elimination of this drug in the body involve a variety of drug-metabolizing enzymes, drug interactions may occur when used concomitantly with other drugs.

Drug Interactions of Mavacamten (CAMZYOS)

Mavacamten is mainly metabolized by CYP2C19 and CYP3A4 enzymes. These enzymes are widely present in the liver and participate in the metabolism of various drugs. When mavacamten is used together with drugs that can affect the activity of these enzymes, drug interactions may occur, resulting in changes in the metabolic rate of mavacamten and affecting its efficacy.

Possibility of other drugs affecting the blood concentration of mavacamten

Mavacamten is mainly metabolized by CYP2C19, followed by CYP3A4 and CYP2C9. Inducers and inhibitors of CYP2C19, as well as moderate to strong inhibitors or inducers of CYP3A4, may affect the exposure of mavacamten.

Possibility of mavacamten affecting the blood concentration of other drugs

Mavacamten is an inducer of CYP3A4, CYP2C9, and CYP2C19. Co-administration with substrates of CYP3A4, CYP2C19, or CYP2C9 may reduce the plasma concentrations of these drugs. Closely monitor the potential reduction in plasma concentrations of these drugs when mavacamten is used in combination with substrates of CYP3A4, CYP2C19, or CYP2C9, as this may reduce their activity.

Drugs that reduce cardiac contractility

Mavacamten is expected to have an additive negative inotropic effect with other drugs that reduce cardiac contractility. Concomitant use of mavacamten in patients taking dipyridamole, ranolazine, verapamil combined with beta-blockers, or diltiazem combined with beta-blockers should be avoided. This is because these drugs and combinations increase the risk of left ventricular systolic dysfunction and heart failure symptoms, and there is limited clinical experience.

If concurrent treatment with negative inotropes is initiated, or the dose of negative inotropes is increased, closely monitor LVEF until a stable dose and clinical response are achieved.